There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

DOI:: 10.1016/j.jval.2020.04.1592

Data availability:

Comments

Comment on this article

scite_

Cited by 1

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
Authors: Christopher Parker, Fei Fei Liu, Kristen A. Deger …

See all cited by

PCN92 Cost-effectiveness analysis of polatuzumab in combination with rituximab and bevacizumab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma

Read this article at